INTELLECTUAL PROPERTY SECURITY AGREEMENT

EX-10.32 13 dex1032.htm INTELLECTUAL PROPERTY SECURITY AGREEMENT, DATED APRIL 30, 2010 Intellectual Property Security Agreement, dated April 30, 2010

 

Execution Copy

Exhibit 10.32

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “Agreement”), dated as of April 30, 2010, is made by PACIRA PHARMACEUTICALS, INC., a California corporation (“Grantor”), in favor of GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation, in its capacity as agent (in such capacity, together with any successors, endorsees and assigns, the “Agent”) for itself and the lenders from time to time party to the Loan Agreement hereinafter defined (collectively, the “Lenders”).

W I T N E S S E T H:

WHEREAS, Grantor, Agent and Lenders are parties to the Loan and Security Agreement, dated as of the date hereof (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which Lenders have agreed to provide to Grantor certain loans and other extensions of credit in accordance with the terms and conditions thereof; and

WHEREAS, pursuant to the Loan Agreement, Grantor is required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and to induce Agent and Lenders to enter into the Loan Agreement and to induce the Lenders to make their respective extensions of credit to the Borrower thereunder, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees with the Agent as follows:

Section 1.    Defined Terms. Capitalized terms used herein without definition are used as defined in the Loan Agreement.

Section 2.    Grant of Security Interest in Intellectual Property Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations hereby mortgages, pledges and hypothecates to Agent, for the benefit of itself and Lenders, and grants to Agent, for the benefit of itself and Lenders, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor (the “Intellectual Property Collateral”):

(a)    all of its trade secrets and rights under any written agreement granting any right to use trade secrets;

(b)    all of its copyrights and rights under any written agreement granting any right to use copyrights, including, without limitation, those referred to on Schedule 1 hereto, together with all renewals, reversions and extensions of the foregoing;

(c)    all of its trademarks and rights under any written agreement granting any right to use trademarks, including, without limitation, those referred to on Schedule 2 hereto, together with all renewals, reversions and extensions of the foregoing;


 

(d)    all goodwill of the business connected with the use of, and symbolized by, each such trademark covered by clause (c) above;

(e)    all of its US patents and rights under any written agreement granting any right to use US patents, including, without limitation, those owned by Grantor referred to on Schedule 3 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(f)    all of its US patent applications and rights under any written agreement granting any right to use US patent applications, including, without limitation, those owned by Grantor referred to on Schedule 4 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(g)    all of its PCT patent applications and rights under any written agreement granting any right to use PCT patent applications, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(h)    all of its foreign patents and patent applications, and rights under any written agreement granting any right to use foreign patents and patent applications, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(i)    all applications, registrations, claims, products, awards, judgments, amendments, improvements and insurance claims related thereto now or hereafter owned or licensed by Grantor, or any claims for damages by way of any past, present, or future infringement of any of the foregoing, together with all accessions and additions thereto, proceeds and products thereof (including, without limitation, any proceeds resulting under insurance policies); provided, further, that the Intellectual Property Collateral shall include, without limitation, all cash, royalty fees, other proceeds, accounts and general intangibles that consist of rights of payment to or on behalf of Grantor or proceeds from the sale, licensing or other disposition of all or any part of, or rights in, the Intellectual Property Collateral by or on behalf of Grantor; and

(j)    all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Notwithstanding the foregoing the term “Intellectual Property Collateral” shall not include and shall exclude all Excluded Assets.

Section 3.    Loan Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with, and is in no way limiting, the security interest granted to Agent, for the benefit of itself and Lenders, pursuant to the Loan Agreement, and Grantor hereby acknowledges and agrees that the rights and remedies of Agent and Lenders with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of each of which are incorporated by reference herein as if fully set forth herein.


 

Section 4.    Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall retain full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Intellectual Property subject to a security interest hereunder.

Section 5.    Counterparts. This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 6.    Governing Law. This Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[Signature Pages Follow]


 

In witness whereof, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

 

GRANTOR:
PACIRA PHARMACEUTICALS, INC.

By:

  /s/ James Scibetta

Name:

  James Scibetta

Title:

  Chief Financial Officer


 

ACCEPTED AND AGREED

as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,

as Agent,

 

By:   /s/ R. Hanes Whiteley
Name:   R. Hanes Whiteley
Title:   Duly Authorized Signatory

 

5


 

Schedule 1

to

Intellectual Property Security Agreement

None.


 

Schedule 2

to

Intellectual Property Security Agreement

US Trademarks – Registered or Applications Pending

 

Mark

   Country    Class    App #      Filing Date      Reg #      Reg Date     

Status

DEPOBUPIVACAINE

   United States    5            3335843         11/13/07       Section 8 Affidavit due 11/13/13

DEPOCYT

   United States    5            2390316         09/26/00      

Renewal

due 09/26/10

DEODUR

   United States    5            2983713         08/09/05       Section 8 Affidavit due 08/09/11

DEPODUR and design

[GRAPHIC APPEARS HERE]

   United States    5            3252733         06/19/07       Section 8 Affidavit due 06/19/13

DEPODUR and design

[GRAPHIC APPEARS HERE]

   United States    16            3127414         08/08/06       Section 8 Affidavit due 08/08/12

DEPOFOAM

   United States    5            3325579         10/30/07       Section 8 Affidavit due 10/30/13

DEPOFOAM

   United States    40, 42            2443719         04/17/01       Renewal due 04/17/11

PACIRA

   United States    5            3648129         06/30/09       Section 8 Affidavit due 06/30/15

PACIRA

   United States    42            3651782         07/07/09       Section 8 Affidavit due 07/07/15


 

Schedule 3

to

Intellectual Property Security Agreement

US Patents – Registered

 

Method for Treating Neurological Disorders

UNITED STATES

   008001    PCIRA.006A    NEW    05/14/1993    08/062,799    10/03/1995    5,455,044    05/14/2013    ISSUED

UNITED STATES

   008002.DIV1    PCIRA.006DVI    DIV    06/07/1995    08/484,501    11/19/1996    5,576,018    11/19/2013    ISSUED

Uniform Spherical Multilamellar Liposomes of Defined and Adjustable Size Distribution

UNITED STATES

   009001    PCIRA.7CP1CP1    NEW    04/25/1990    07/514,665    12/22/1992    5,173,219    12/22/2009    ISSUED

Heterovesicular Liposomes (to 020001)

UNITED STATES

   016001    PCIRA.9CP1CP1    NEW    06/16/1993    08/078,701    06/06/1995    5,422,120    06/16/2013    ISSUED

Preparation of Multivesicular Liposomes for Controlled release of Biologically Active Compounds

UNITED STATES

   019001    PCIRA.012A    NEW    09/13/1994    08/305,158    11/30/1999    5,993,850    11/30/2016    ISSUED

Heterovesicular Liposomes

UNITED STATES

   020001    PCIRA.9CPCPCP    CIP    02/23/1995    08/393,724    11/19/1996    5,576,017    06/06/2012    ISSUED

Epidural Administration of Therapeutic Compounds with Sustained Rate of Release

UNITED STATES

   021001    PCIRA.013A    NEW    07/14/1995    08/502,569    08/03/1999    5,931,809    07/14/2015    ISSUED

UNITED STATES

   021002    PCIRA.013C1    CON    09/16/1997    08/931,867    08/06/2002    6,428,529    07/14/2015    ISSUED

Multivesicular Liposomes for Controlled Release of Encapsulated Biologically Active Substances

UNITED STATES

   022002.DIV1    PCIRA.5CPCDV1    DIV    03/20/1998    09/045,236    10/17/2000    6,132,766    11/16/2013    ISSUED

Multivesicular Liposomes for Controlled Release of Encapsulated Biologically Active Substances

UNITED STATES

   023001    PCIRA.005CP2C1    R62    05/23/1997    08/862,589    06/16/1998    5,766,627    11/16/2013    ISSUED

Multivesicular Liposomes Having a Biologically Active Substance Encapsulated Therein in the Presence of a Hydrochloride

UNITED STATES

   024001    PCIRA.8PPCPCCP    CIP    06/06/1995    08/473,019    09/15/1998    5,807,572    09/15/2015    ISSUED

Multivesicular Liposomes Having a Biologically Active Substance Encapsulated Therein in the Presence of a Hydrochloride

UNITED STATES

   025001    PCIRA.8CPPCPCCP    CIP    06/06/1995    08/472,126    03/03/1998    5,723,147    03/03/2015    ISSUED

Cyclodextrin Liposomes Encapsulating Pharmacologic Compounds and Methods for Their Use

UNITED STATES

   027001    PCIRA.010NP    CIP    12/21/1995    08/535,256    06/02/1998    5,759,573    04/22/2014    ISSUED

Method for Producing Liposomes with Increased Percent of Compound Encapsulated

UNITED STATES

   030001    PCIRA.018A    NEW    10/01/1996    08/723,583    12/07/1999    5,997,899    10/01/2016    ISSUED

UNITED STATES

   030002.DIV1    PCIRA.018DV3    DIV    11/01/1999    09/431,525    01/09/2001    6,171,613    10/01/2016    ISSUED

UNITED STATES

   030003.DIV1    PCIRA.018DV1    DIV    11/01/1999    09/431,523    02/27/2001    6,193,998    10/01/2016    ISSUED

UNITED STATES

   030005.CON1    PCIRA.018C1    CON    12/06/1999    09/454,521    06/05/2001    6,241,999    16/01/2016    ISSUED

Method for Utilizing Neutral Lipids to Modify In Vivo Release from Multivesicular Liposomes

UNITED STATES

   033001    PCIRA.021A    NEW    01/31/1997    08/792,566    04/06/1999    5,891,467    01/31/2017    ISSUED

UNITED STATES

   033002    PCIRA.021DV1    DIV    11/19/1997    08/974,296    10/05/1999    5,962,016    01/31/2017    ISSUED

Modulation of Drug Loading in Multivesicular Liposomes

UNITED STATES

   039001    PCIRA.015A    NEW    09/08/1997    08/925,532    08/22/2000    6,106,858    09/08/2017    ISSUED

Sustained Release Liposomal Anesthetic Compositions

UNITED STATES

   041US1    PCIRA.014A    FCA    09/18/1998    09/156,214    04/04/2000    6,045,824    09/18/2018    ISSUED

Biodegradable Compositions for the Controlled Release of Encapsulated Substances

UNITED STATES

   051001    PCIRA.020A    FCA    07/16/1999    09/356,218    08/21/2001    6,277,413    07/16/2019    ISSUED

UNITED STATES

   051002.DIV1    PCIRA.020DV1    DIV    05/17/2001    09/859,847    09/21/2004    6,793,938    08/14/2019    ISSUED


 

Schedule 4

to

Intellectual Property Security Agreement

US Patents: Pending

 

Sustained Release Liposomal Anesthetic Compositions

UNITED STATES

   041002.CONWO    PCIRA.014C1    DCA    04/01/2005    11/097,756             PENDING

Production of Multivesicular Liposomes

UNITED STATES

   043002    PCIRA.019C1    FCA    02/25/2007    11/678,615             PENDING

Encapsulation of Nanosuspensions in Liposomes and Microspheres

UNITED STATES

   080001    PCIRA.017A    FCA    05/31/2002    10/161,969             PENDING

Process for Manufacturing Multivesicular Liposomes

UNITED STATES

   096PO1       NEW                   PROPOSED
Hyaluronidase As An Adjuvant For Increasing The Injection Volume And Dispersion Of Large Diameter Synthetic Membrane Vesicles Containing A Therapeutic Agent

UNITED STATES

   032PR    PCIRA.032PR    PRO    05/29/2009    61/182367             PENDING